Identification of novel ligands for the Gabapentin binding site on the α2δ subunit of a calcium channel and their evaluation as anticonvulsant agents

Journal of Medicinal Chemistry

Volumn 41, Issue 11, 1998, Pages 1838-1845

  Bryans, Justin S ^a   Davies, Natasha ^a   Gee, Nicolas S ^a   Dissanayake, Visaka U K ^a   Ratcliffe, Giles S ^a   Horwell, David C ^a   Kneen, Clare O ^a   Morrell, Andrew I ^a   Oles, Ryszard J ^a   O'Toole, John C ^a   Perkins, Gemma M ^a   Singh, Lakhbir ^a   Suman Chauhan, Nirmala ^a   O'Neill, Jacqueline A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ANTICONVULSIVE AGENT; CALCIUM CHANNEL; GABAPENTIN; UNCLASSIFIED DRUG; [1 (AMINOMETHYL) 3 METHYLCYCLOHEXYL]ACETIC ACID HYDROCHLORIDE;

ALPHA CHAIN; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; DOSE RESPONSE; DRUG BINDING SITE; DRUG STRUCTURE; DRUG SYNTHESIS; EPILEPSY; LIGAND BINDING; STRUCTURE ACTIVITY RELATION;

EID: 14444278052     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970649n     Document Type: Article

References (19)

1. Taylor, C. P. The Role of Gabapentin. In New Trends in Epilepsy Management; Chadwick, D., Ed.; Royal Society of Medicine Services Ltd.: London, 1993; pp 13-40.
2. Singh, L.; Field, M. J.; Ferris, P.; Hunter, J. C.; Oles, R. J.; Williams, R. G.; Woodruff, G. N. The antiepileptic agent Gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psycopharmacol. Berl. 1996, 127 (1), 1-9.
3. Rosner, H.; Rubin, L.; Kestenbaum, A. Gabapentin adjunctive therapy in neuropathic pain states. Clin. J. Pain 1996, 12 (1), 56-8.
4. Zapp, J. J. Postpoliomyelitis pain treated with Gabapentin. Am. Fam. Physician 1996, 53 (8), 2442, 2445.
5. Satzinger, G. Antiepileptics from gamma-aminobutyric acid. Arzneimittelforschung 1994, 44, 261-6.
6. Nanavati, S. M.; Silverman, R. B. Design of potential anticonvulsant agents: mechanistic classification of GABA aminotransferase inactivates. J. Med. Chem. 1989, 32, 2413-21.
7. B receptors as targets for drug action. Arzneimittelforschung 1992, 42 (2A), 215-23.
8. Taylor, C. P. Emerging perspectives on the mechanism of action of Gabapentin. Neurology 1994, 44, S10-16.
9. 3H]Gabapentin may label a system-L-like neutral amino acid carrier in brain. Eur. J. Pharmacol. 1993, 247, 341-55.
10. McLean, M. J. Gabapentin. Epilepsia 1995, 36, S73-86.
11. Beydoun, A.; Uthman, B. M.; Sackellares, J. C. Gabapentin: pharmacokinetics, efficacy, and safety. Clin. Neuropharmacol. 1995, 18 (6), 469-81.
12. 3H]gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur. J. Pharmacol. 1993, 244, 293-301.
13. 3H]Gabapentin to a novel site in rat brain: autoradiographic studies. Eur. J. Pharmacol. 1993, 244, 303-9.
14. 2δ subunit of a calcium channel. J. Biol. Chem. 1996, 271 (10), 5768-76.
15. 2δ subunit of a calcium channel. BioOrg. Med. Chem. Lett. 1997, 7 (19), 2481-4.
16. Bryans, J. S.; Horwell, D. C.; Ratcliffe, G. S. Unpublished results.
17. Griffiths, G.; Mettler, H.; Mills, L. S.; Previdoli, F. Novel syntheses of Gabapentin via addition of hydrocyanic acid to cyclohexylidenemalonate or cyano(cyclohexylidene)acetate. Helv. Chim. Acta 1991, 74, 309-14.
18. Nagata, W.; Yoshioka, M. Hydrocyanation of conjugated carbonyl compounds. Org. React. 1977, 25, 255-476.
19. Gassman, P. G.; Marshall, J. L. Bicyclo[2,2,1]hepten-7-one. Organic Syntheses; Wiley: New York, 1973; Coll. Vol. 5, pp 91, 424.